Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.
Obesity is a major health care concern because of its associated medical complications and increased mortality . Despite a myriad of short-term weight loss strategies and the motivation of improving health , patients have difficulty maintaining reduced weight . Pharmacologic agents , such as fluoxetine , a selective serotonin uptake inhibitor , have been investigated as adjunctive therapy to st and ard weight management programs . Extended therapy with fluoxetine has demonstrated clinical ly meaningful benefits on weight loss and obesity-associated medical conditions in double-blind placebo-controlled studies . However , the magnitude of these benefits for individuals vary . Such findings are consistent with the belief that the obesity syndrome has differing etiologies . Accordingly not all patients are likely to benefit from a particular therapy . Studies should identify patient subgroups that are more likely to respond to a specific therapy . In this study of 719 fluoxetine-treated and 722 placebo treated patients in four multicenter , r and omized , double-blind , long-term clinical trials , we investigated possible predictors of a beneficial long-term outcome from fluoxetine therapy . Patients ' age , current smoking activity , and baseline uric acid concentration were predictors of a meaningful long-term treatment effect . Further review of the weight loss patterns of patients achieving long-term success provided the basis for a treatment monitor . Use of the predictors and the treatment monitor are strategies to maximize the benefits of therapy through improved patient selection and monitoring during a therapeutic program
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .